Flagship Pioneering-backed Sail Biomedicines has laid off 12 employees following a review of the company’s organizational ...

The maker of the FDA’s only approved total artificial heart has outlined plans to go public, with a $12 million IPO, ...

Vence Bonham Jr., the highest ranking official at the National Human Genome Research Institute (NHGRI), has been put on ...

A federal judge in Texas has blocked the FDA’s plans to bring laboratory-developed tests under the same regulations it uses ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

| Project Optimus is changing the landscape of oncology drug development by redefining dose optimization standards. Learn how ...

The biotech, which has raised more than $140 million over several investment rounds in the last few years from the likes of ...